This is a phase I study investigating the toxicity and the potential efficacy of thalidomide and oral cyclophosphamide in patients with hormone refractory prostate cancer (HRPC), previously treated with docetaxel-based regimens
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial / Giuseppe Di, Lorenzo; Riccardo, Autorino; DE LAURENTIIS, Michelino; Valeria, Forestieri; Carmela, Romano; Antonella, Prudente; Francesco, Giugliano; Ciro, Imbimbo; Vincenzo, Mirone; DE PLACIDO, Sabino. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - STAMPA. - 6:(2007), pp. 313-317.
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
DE LAURENTIIS, MICHELINO;DE PLACIDO, SABINO
2007
Abstract
This is a phase I study investigating the toxicity and the potential efficacy of thalidomide and oral cyclophosphamide in patients with hormone refractory prostate cancer (HRPC), previously treated with docetaxel-based regimensI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
